Browsing Tag
KEYNOTE-D46
1 post
Gilead’s Trodelvy-Keytruda lung cancer combination misses Phase III endpoints despite higher response rate
Trodelvy plus Keytruda increased response rates and numerically lengthened progression-free survival in EVOKE-03, but the Phase III study failed its statistical endpoints and produced no overall survival advantage.